UK Pharma Regulator Could Approve Novo Nordisk’s Wegovy Weight‑Loss Pill by End of 2026

Britain’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), said on Monday it is currently reviewing an application from Danish pharmaceutical giant Novo Nordisk for its oral 25‑milligram version of the weight‑loss drug Wegovy, a pill form of semaglutide that is taken once daily. The MHRA anticipates making a final decision on whether to approve the pill in the UK by the end of 2026, giving patients a new non‑injectable treatment option for obesity. Novo Nordisk launched this new Wegovy pill in the United States the same day, aiming to regain market share from competitor Eli Lilly and appeal to consumers who prefer pills over injectable medications. The company also submitted approval applications for the pill to the European Medicines Agency and other international regulatory bodies in the second half of 2025 as part of its global rollout strategy. If approved, the pill could broaden access to GLP‑1‑based weight‑loss treatments in the UK and represent a significant step in obesity‑care options amid rising demand for oral therapies. #NovoNordisk #Wegovy #PharmaRegulation #WeightLossPill #SlimScan #GrowthStocks #CANSLIM